122 related articles for article (PubMed ID: 17919337)
1. The radiosensitizing effect of doranidazole on human colorectal cancer cells exposed to high doses of irradiation.
Zhang L; Gong A; Ji J; Wu Y; Zhu X; Lv S; Lv H; Sun X
BMC Cancer; 2007 Oct; 7():188. PubMed ID: 17919337
[TBL] [Abstract][Full Text] [Related]
2. Effect of a hypoxic cell sensitizer doranidazole on the radiation-induced apoptosis of mouse L5178Y lymphoma cells.
Aoki M; Furusawa Y; Shibamoto Y; Kobayashi A; Tsujitani M
J Radiat Res; 2002 Jun; 43(2):161-6. PubMed ID: 12238330
[TBL] [Abstract][Full Text] [Related]
3. Effects of hypoxic cell radiosensitizer doranidazole (PR-350) on the radioresponse of murine and human tumor cells in vitro and in vivo.
Yahiro T; Masui S; Kubota N; Yamada K; Kobayashi A; Kishii K
J Radiat Res; 2005 Sep; 46(3):363-72. PubMed ID: 16210793
[TBL] [Abstract][Full Text] [Related]
4. In vivo efficacy and pharmacokinetics of a new hypoxic cell radiosensitizer doranidazole in SUIT-2 human pancreatic cancer xenografted in mouse pancreas.
Matsuoka H; Shibamoto Y; Kubota T; Tsujitani M; Majima T
Oncol Rep; 2000; 7(1):23-6. PubMed ID: 10601585
[TBL] [Abstract][Full Text] [Related]
5. Enhanced local tumour control after single or fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazole.
Murata R; Tsujitani M; Horsman MR
Radiother Oncol; 2008 Jun; 87(3):331-8. PubMed ID: 18375007
[TBL] [Abstract][Full Text] [Related]
6. Radiosensitivity of human pancreatic cancer cells in vitro and in vivo, and the effect of a new hypoxic cell sensitizer, doranidazole.
Shibamoto Y; Kubota T; Kishii K; Tsujitani M
Radiother Oncol; 2000 Aug; 56(2):265-70. PubMed ID: 10927148
[TBL] [Abstract][Full Text] [Related]
7. The prospective application of a hypoxic radiosensitizer, doranidazole to rat intracranial glioblastoma with blood brain barrier disruption.
Yasui H; Asanuma T; Kino J; Yamamori T; Meike S; Nagane M; Kubota N; Kuwabara M; Inanami O
BMC Cancer; 2013 Mar; 13():106. PubMed ID: 23496909
[TBL] [Abstract][Full Text] [Related]
8. Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines.
van Nifterik KA; van den Berg J; Stalpers LJ; Lafleur MV; Leenstra S; Slotman BJ; Hulsebos TJ; Sminia P
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1246-53. PubMed ID: 17967314
[TBL] [Abstract][Full Text] [Related]
9. Phase Ia study of a hypoxic cell sensitizer doranidazole (PR-350) in combination with conventional radiotherapy.
Nemoto K; Shibamoto Y; Ohmagari J; Baba Y; Ebe K; Ariga H; Takai Y; Ouchi A; Sasai K; Shinozaki M; Tsujitani M; Sakaguchi M; Yamada S; Sakamoto K
Anticancer Drugs; 2001 Jan; 12(1):1-6. PubMed ID: 11272282
[TBL] [Abstract][Full Text] [Related]
10. Modulating Survivin as a Radioresistant Factor, Caspase-3, and Apoptosis by Omega-3 Docosahexaenoic Acid Sensitizes Mutant-p53 Colorectal Cancer Cells to γ-Irradiation.
Hosseini F; Sam MR; Jabbari N; Mozdarani H
Cancer Biother Radiopharm; 2018 Nov; 33(9):387-395. PubMed ID: 30395490
[TBL] [Abstract][Full Text] [Related]
11. Preclinical study on hypoxic radiosensitizing effects of glycididazole in comparison with those of doranidazole
Yasui H; Kubota N; Nishizumi J; Sakai Y; Yamamori T; Inanami O
Oncol Lett; 2018 Feb; 15(2):1993-1998. PubMed ID: 29434899
[TBL] [Abstract][Full Text] [Related]
12. A nitroimidazole derivative, PR-350, enhances the killing of pancreatic cancer cells exposed to high-dose irradiation under hypoxia.
Mizumoto K; Qian LW; Zhang L; Nagai E; Kura S; Tanaka M
J Radiat Res; 2002 Mar; 43(1):43-51. PubMed ID: 12056329
[TBL] [Abstract][Full Text] [Related]
13. Radiation-chemical properties of the hypoxic cell radiosensitizer doranidazole (PR-350).
Kuwabara M; Iida Y; Inanami O; Sawamura S; Yokoyama K; Tsujitani M
J Radiat Res; 2002 Mar; 43(1):77-88. PubMed ID: 12056332
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer: long-term results of a placebo-controlled randomised study.
Karasawa K; Sunamura M; Okamoto A; Nemoto K; Matsuno S; Nishimura Y; Shibamoto Y
Radiother Oncol; 2008 Jun; 87(3):326-30. PubMed ID: 18342968
[TBL] [Abstract][Full Text] [Related]
15. Low dose fractionated radiation enhances the radiosensitization effect of paclitaxel in colorectal tumor cells with mutant p53.
Chendil D; Oakes R; Alcock RA; Patel N; Mayhew C; Mohiuddin M; Gallicchio VS; Ahmed MM
Cancer; 2000 Nov; 89(9):1893-900. PubMed ID: 11064345
[TBL] [Abstract][Full Text] [Related]
16. Radiosensitizing Effect of P2X7 Receptor Antagonist on Melanoma in Vitro and in Vivo.
Tanamachi K; Nishino K; Mori N; Suzuki T; Tanuma SI; Abe R; Tsukimoto M
Biol Pharm Bull; 2017 Jun; 40(6):878-887. PubMed ID: 28344198
[TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid is an effective radiosensitizer in the treatment of osteosarcoma.
Kim EH; Kim MS; Lee KH; Koh JS; Jung WG; Kong CB
Oncotarget; 2016 Oct; 7(43):70869-70880. PubMed ID: 27765919
[TBL] [Abstract][Full Text] [Related]
18. Exploring the radiosensitizing potential of AZD8931: a pilot study on the human LoVo colorectal cancer cell line.
Antognelli C; Palumbo I; Piattoni S; Calzuola M; Del Papa B; Talesa VN; Aristei C
Int J Radiat Biol; 2020 Nov; 96(11):1504-1512. PubMed ID: 32910714
[TBL] [Abstract][Full Text] [Related]
19. Radiosensitization by irinotecan is attributed to G2/M phase arrest, followed by enhanced apoptosis, probably through the ATM/Chk/Cdc25C/Cdc2 pathway in p53-mutant colorectal cancer cells.
Wang Y; Yang L; Zhang J; Zhou M; Shen L; Deng W; Liang L; Hu R; Yang W; Yao Y; Zhang H; Zhang Z
Int J Oncol; 2018 Oct; 53(4):1667-1680. PubMed ID: 30085332
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer.
Verstraete M; Debucquoy A; Gonnissen A; Dok R; Isebaert S; Devos E; McBride W; Haustermans K
BMC Cancer; 2015 Dec; 15():946. PubMed ID: 26675289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
